CD7 CAR T-Cell Therapy Plus Allogeneic HSCT Is Safe, Feasible in CD7+ Hematologic Malignancies

Sequential CD7 CAR T-cell therapy plus haploidentical HSCT without GVHD prophylaxis is effective and safe in CD7-positive hematologic malignancies.

Related Keywords

China ,Zhejiang ,Hangzhou , ,Zhejiang University School Of Medicine ,New England Journal ,Bone Marrow Transplantation Center ,First Affiliated Hospital ,Zhejiang University School ,Che Huang ,D ,Phd ,Cart Cell Therapy ,Nct04599556 ,Relapsed Refractory Cd7 Positive Hematologic Malignancies ,